Adma Biologics price target raised to $26 from $18 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Adma Biologics (ADMA) to $26 from $18 and keeps a Buy rating on the shares. The company reported a substantial top- and bottom-line outperformance and its guidance was increased yet again, the analyst tells investors in a research note.